Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
Teva prices $4.9 billion equivalent in new senior notes to fund conditional redemptions of several existing higher-coupon bond series and other corporate uses.
Rhea-AI Summary
Teva Pharmaceutical Industries (TEVA) has priced approximately $4.9 billion (equivalent) of new senior notes across five euro- and dollar-denominated tranches to refinance existing debt. The new issues comprise €1.0 billion of 4.250% notes due 2033, €500 million of 4.625% notes due 2036, $1.0 billion of 5.500% notes due 2034, $1.0 billion of 5.750% notes due 2037, and $1.2 billion of 5.250% notes due 2032, issued by Teva Finance II, III and IV and guaranteed on a senior unsecured basis by Teva.
Settlement is expected around September 16, 2026, subject to customary conditions. Teva expects to use net proceeds plus cash on hand to fund conditional redemptions of multiple outstanding series, including all 6.750% notes due 2028, all 7.875% and 7.375% sustainability-linked notes due 2029, up to $450 million of 4.750% sustainability-linked notes due 2027, and up to €1.15 billion of 4.375% sustainability-linked notes due 2030, as well as fees, expenses and general corporate purposes.
Positive
- $4.9 billion equivalent in new senior notes successfully priced across five tranches
- New euro tranches of €1.5 billion total with coupons of 4.250% (2033) and 4.625% (2036)
- New dollar tranches of $3.2 billion total with coupons of 5.250–5.750% maturing 2032–2037
- Company intends to redeem all 6.750% notes due 2028 and 7.875% and 7.375% sustainability-linked notes due 2029
- Planned redemptions include up to $450 million of 4.750% sustainability-linked notes due 2027
- Planned redemption amount for 4.375% sustainability-linked notes due 2030 set at up to €1.15 billion
Negative
- None.
News Explained
Beyond the redemptions already described, Teva said it expects on
Key Figures
- Senior notes offering
- $4.9 billion (equivalent)
- Successfully priced offering
- EUR senior notes
- €1,000,000,000 at 4.250%
- Maturing in 2033
- EUR senior notes
- €500,000,000 at 4.625%
- Maturing in 2036
- USD senior notes
- $1,000,000,000 at 5.500%
- Maturing in 2034
- USD senior notes
- $1,000,000,000 at 5.750%
- Maturing in 2037
- USD senior notes
- $1,200,000,000 at 5.250%
- Maturing in 2032
- Expected settlement
- September 16, 2026
- Subject to customary closing conditions
- Reduced redemption amount
- €1,150,000,000
- Sustainability-linked senior notes due 2030
Historical Context
-
S&P raised Teva to BBB-, completing investment-grade ratings across covered agencies.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
senior notes financial
conditional redemptions financial
sustainability-linked senior notes financial
automatic shelf registration statement regulatory
form s-3 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
TEL AVIV, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully priced its offering of approximately
The Notes that successfully priced today consist of (i) Teva Pharmaceutical Finance Netherlands II B.V.’s (“Teva Finance II”)
The settlement of the Notes is expected to occur on or about September 16, 2026, subject to customary closing conditions. The settlement of the Notes in the amount indicated herein will satisfy the condition of the Conditional Redemptions that the applicable Issuers receive funding in an amount satisfactory to each such Issuer and in any case sufficient to pay the redemption price for the applicable series of notes in full and to cover all related expenses.
The Notes will be unsecured senior obligations of the Issuers and will be unconditionally guaranteed on a senior unsecured basis by Teva.
In connection with the Conditional Redemptions, Teva issued notices of conditional redemption on September 8, 2026, pursuant to which it intends to redeem in accordance with the terms set forth in the relevant indentures: (i) all of the
The offering and sale of the Notes were made pursuant to our effective automatic shelf registration statement on Form S-3, including our base prospectus, filed with the Securities and Exchange Commission (the “SEC”) on February 7, 2025. The offering of these Notes was made only by means of a prospectus supplement and accompanying base prospectus, which have been filed with the SEC. Before you invest, you should read the prospectus supplement and accompanying prospectus along with other documents that Teva has filed with the SEC and that are incorporated by reference into the prospectus supplement and accompanying base prospectus for more complete information about Teva and this offering. These documents are available at no charge by visiting EDGAR on the SEC website at http://www.sec.gov. Alternatively, a copy of the prospectus supplement and accompanying base prospectus related to this offering may be obtained, when available, by contacting BNP PARIBAS, 16, boulevard des Italiens, 75009 Paris, France, Attention: Fixed Income Syndicate (emails: dl.syndsupportbonds@uk.bnpparibas.com); BNP Paribas Securities Corp., 787 Seventh Avenue, New York, New York 10019, United States of America, Attention: Debt Syndicate Desk (email: DL.US.Syndicate.Support@us.bnpparibas.com); Citigroup Global Markets Europe AG or Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, United States of America, Telephone: (800) 831-9146, E-mail: prospectus@citi.com; Goldman Sachs Bank Europe SE, Marienturm, Taunusanlage 9-10, 60329 Frankfurt am Main, Germany, Attention: High Yield Syndicate Desk (Tel: +49 69 7532 1000, Fax: +44 (0)207 774 2330); J.P. Morgan SE, Taunustor 1 (TaunusTurm), 60310 Frankfurt am Main, Germany, Attention: Head of EMEA Capital Markets Group (email: Head_of_EMEA_DCMG@jpmorgan.com) and J.P. Morgan Securities LLC, 270 Park Avenue, New York, New York 10017, United States of America, Attention: Investment Grade Syndicate Desk, Tel: (212) 834-6081).
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: completion of the offering of senior notes and conditional redemptions for certain outstanding notes; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; and our potential need to raise additional funds in the future, which may not be available on acceptable terms or at all; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2026, in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Forward Looking Statements,” and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. No assurance can be given that the transactions described herein will be consummated or as to the ultimate terms of any such transactions.
It may be unlawful to distribute this press release in certain jurisdictions. This press release is not for distribution in Canada, Japan or Australia. The information in this press release does not constitute an offer of securities for sale in Canada, Japan or Australia.
The Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area (“EEA”). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, “MiFID II”); or (ii) a customer within the meaning of Directive 2016/97/EU (as amended, the “Insurance Distribution Directive”), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined in Article 2 of Regulation (EU) 2017/1129. Consequently, no key information document required by Regulation (EU) No 1286/2014 (as amended, the “PRIIPs Regulation”) for offering or selling the Notes or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the Notes or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation.
The Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investors in the United Kingdom. For these purposes, the expression “retail investor” means a person who is either one (or both of the following): (i) not a professional client, as defined in point (8) of Article 2(1) of Regulation (EU) No. 600/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018; or (ii) not a qualified investor as defined in paragraph 15 of Schedule 1 to the Public Offers and Admission to Trading Regulations 2024. Consequently, no disclosure document required by FCA Product Disclosure Sourcebook (“DISC”) for offering, selling, or distributing the Notes or otherwise making them available to retail investors in the UK has been prepared and, therefore, offering, selling, or distributing the notes or otherwise making them available to any retail investor in the UK may be unlawful under the DISC and the Consumer Composite Investments (Designated Activities) Regulations 2024.
Promotion of the Notes in the United Kingdom is restricted by the Financial Services and Markets Act 2000 (“FSMA”), and accordingly, the Notes are not being promoted to the general public in the United Kingdom. This announcement is for distribution only to, and is only directed at (i) persons who are outside the United Kingdom or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), (iii) high net worth entities, and other persons to whom they may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order or (iv) persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) in connection with the issue or sale of any notes may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “relevant persons”).The Notes will only be available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such Notes will be engaged in only with, relevant persons. This announcement is directed only at relevant persons and must not be acted on or relied on by anyone who is not a relevant person.
The Notes have not, may not and will not be offered, sold or delivered in the Netherlands, other than to qualified investors (as defined in Regulation (EU) 2017/1129).
The Notes have not, may not and will not be offered, sold or delivered in Israel, other than to persons who qualify as one of the types of investors listed in the First Addendum to the Israeli Securities Law, subject to and in accordance with the requirements set forth in the First Addendum to the Israeli Securities Law.
Teva Media Inquiries:
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquiries:
TevaIR@Tevapharm.com
Source: Teva Pharmaceutical Industries Ltd
FAQ
What are the detailed terms and maturities of Teva’s newly priced senior notes?
The new offering consists of five tranches: (i) €1,000,000,000 of 4.250% senior notes due 2033 and (ii) €500,000,000 of 4.625% senior notes due 2036, both issued by Teva Pharmaceutical Finance Netherlands II B.V.; (iii) $1,000,000,000 of 5.500% senior notes due 2034 and (iv) $1,000,000,000 of 5.750% senior notes due 2037, both issued by Teva Pharmaceutical Finance Netherlands III B.V.; and (v) $1,200,000,000 of 5.250% senior notes due 2032 issued by Teva Pharmaceutical Finance Netherlands IV B.V. All notes are senior unsecured obligations of the issuers and are guaranteed on a senior unsecured basis by Teva.
When is settlement of the new notes expected and what condition do they satisfy?
Settlement of the notes is expected to occur on or about September 16, 2026, subject to customary closing conditions. Settlement of the notes in the stated aggregate amount will satisfy the condition that the issuers receive funding in an amount satisfactory to them and sufficient to pay the redemption price of the applicable series of notes in full and to cover all related expenses for the conditional redemptions.
Which existing Teva notes are subject to conditional redemption funded by this offering?
Teva has issued notices of conditional redemption for: (i) all 6.750% senior notes due 2028, (ii) all 7.875% sustainability-linked senior notes due 2029, (iii) all 7.375% sustainability-linked senior notes due 2029, (iv) up to $450,000,000 of 4.750% sustainability-linked senior notes due 2027, and (v) up to €1,250,000,000 of 4.375% sustainability-linked senior notes due 2030, with an intended reduction of the latter amount to up to €1,150,000,000. Teva also expects to issue a notice of conditional redemption to redeem all 8.125% USD sustainability-linked senior notes due 2031.
Can Teva change the scope of its conditional redemptions?
Teva may, in its sole discretion, issue additional notices of conditional redemption for other outstanding notes or amend the principal amounts to be redeemed under existing notices, in each case in accordance with the relevant indentures. The company is not obligated to make such additional changes.
How can investors access the prospectus and offering documents for the new notes?
The notes were offered under an automatic shelf registration statement on Form S-3 and related base prospectus filed with the U.S. Securities and Exchange Commission. The prospectus supplement and accompanying base prospectus are available free of charge via the SEC’s EDGAR system at http://www.sec.gov. Copies may also be requested from the listed joint bookrunners, including BNP Paribas, Citigroup Global Markets, Goldman Sachs Bank Europe SE and J.P. Morgan at the contact details provided in the announcement.
Are the new notes available to retail investors in the EEA and the United Kingdom?
The notes are not intended to be offered, sold or otherwise made available to retail investors in the European Economic Area or the United Kingdom. No key information document under the PRIIPs Regulation has been prepared for EEA retail investors, and no disclosure document under the FCA Product Disclosure Sourcebook has been prepared for UK retail investors, so making the notes available to such investors may be unlawful under the applicable regimes.
Are there any geographic restrictions on where Teva’s notes may be offered?
The notes will only be promoted in the United Kingdom to persons falling within specified professional or high net worth categories ("relevant persons") and must not be relied upon by others. In the Netherlands, the notes have not, may not and will not be offered, sold or delivered other than to qualified investors as defined in Regulation (EU) 2017/1129. In Israel, they have not, may not and will not be offered, sold or delivered other than to investors listed in the First Addendum to the Israeli Securities Law, in accordance with its requirements.